cerdelga
(eliglustat)Genzyme Corporation
Usage: CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are categorized as extensive, intermediate, or poor CYP2D6 metabolizers, as determined by an FDA-cleared test. Limitations apply for ultra-rapid metabolizers and indeterminate genotypes.